MI Bioresearch has been sold to Covance, a subsidiary of LabCorp

MI Bioresearch is a leading preclinical immuno-oncology / oncology contract research organization, offering a unique combination of complementary services. It supports preclinical research for a diverse pharmaceutical and biotechnology customer base. It offers a broad range of human cell line and syngeneic models, supported by an array of in vitro services, in vivo pharmacology, in vivo imaging and focal beam radiation. MI Bioresearch’s comprehensive, differentiated business model leverages this range of services to better interrogate the complex pharmacology associated with cancer to provide higher-quality, decision-enabling data to its customers. For more information, visit www.mibioresearch.com.

Lincoln International acted as the exclusive investment banking advisor for MI Bioresearch and its shareholders, working closely with the company’s management team and shareholders throughout the sale process. This included creating a customized process strategy, developing the positioning, managing the buyer outreach, organizing due diligence and negotiating the transaction.

About Covance

Covance is a comprehensive drug development company. Covance offers laboratory testing services to the chemical / agrochemical industries and is a market leader in toxicology services, central laboratory services, discovery services and a top global provider of Phase III clinical trial management services. For more information, visit www.covance.com.

About LabCorp

LabCorp, an S&P 500 listed company, is a leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. LabCorp delivers diagnostic solutions, brings innovative medicines to patients and develops technology-enabled solutions. For more information, visit www.labcorp.com.

Share: